Discontinuation-driven weight regain and lean mass dynamics: Implications for sustained metabolic healthspan with GLP-1 RAs

Researka accepted publication: faf58aa1-0279-46d8-a52f-a9e3f585c07c Source submission: 49d6d6b1-4809-4844-9a20-e342e88b92ca The direct receipts support a narrow working claim: The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk; Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim. Reviewer revision: The memo is narrowed to the direct receipts named below. Treat the lead claim as hypothesis-generating; broader context is background only unless it shares the same endpoint, comparator, and population.